Insulin Glulisine: 4 agencies, 2004–2016
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
No agency in this archive has refused insulin glulisine: all 5 decisive outcomes across 4 agencies were positive or positive with restrictions.
Assessment has run over 11.2 years, from 3 Dec 2004 at TLV (Sweden) to 3 Feb 2016 at HAS (France).
No assessment is on file from PBAC (Australia), AWMSG (Wales), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
Nothing has been added since 2016; on this evidence the file is dormant.
TLV (Sweden) was first to assess insulin glulisine, on 3 Dec 2004; PHARMAC (New Zealand) did not open a file until 12 Nov 2009 — a wide spread of 4.9 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 3 of 7 dated records fall in 2008 alone.
Restriction is doing real work here: 2 of 5 decisive outcomes narrowed insulin glulisine to a subgroup rather than accepting or refusing it outright, at SMC (Scotland).
2 of the 4 agencies here assessed insulin glulisine more than once, HAS (France) most often at 3 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 4 of the 18 agencies here have assessed insulin glulisine.
The full ledger for insulin glulisine reads 3 recommended, 2 other and 2 restricted.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 3 Feb 2016 | Listing renewal (Transparency Committee) | SMR substantial | source |
| PHARMAC (New Zealand) | 12 Nov 2009 | Type I and Type II Diabetes | PTAC advice: Cost Neutral · decision reached | source |
| SMC (Scotland) | 10 Nov 2008 | For adolescents and children with diabetes mellitus | accepted (restricted) | source |
| SMC (Scotland) | 7 Apr 2008 | Treatment of adult patients with diabetes mellitus | accepted (restricted) | source |
| TLV (Sweden) | 3 Dec 2004 | LFN bifaller ansökan om Apidra | general subsidy | source |
2 further decisions for insulin glulisine, across 1 agency, are not shown here.
Related molecules
- insulin detemir — divergent outcome (recommended vs restricted) on a shared indication
- insulin glargine — same ATC class A10A — Diabetes
- insulin aspart — same ATC class A10A — Diabetes
- insulin degludec — same ATC class A10A — Diabetes
- insulin lispro — same ATC class A10A — Diabetes
- insulin glargine / lixisenatide — same ATC class A10A — Diabetes
Coverage: 7 decisions for insulin glulisine from 4 agencies, 2004 to 2016. Data to 7 Sep 2026. ATC class A10A — Diabetes. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.